DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Di Leo A, Jerusalem G, Petruzelka L. et al
CONFIRM: A phase III, randomized, parallel-group, trial comparing fulvestrant 250 mng vs. fulvestrant 500 mng in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Cancer Res 2009; 69 (Suppl.): 491 s-
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.